Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Mochida: Operating Profits Up 34% Driven by Good Sales of Epadel, Atelec
November 26, 2007
- Taiyo: Sales Up 7%, Operating Profits Down 1%
November 26, 2007
- Kissei: Urief, Glufast Surge, Bezatol, Cabaser Sink
November 26, 2007
- Towa: Profits Leap as a Result of Focus on Top-Priority Products
November 26, 2007
- Nippon Shinyaku Aims at Developing Many Medium-Sized Products: President Maekawa
November 26, 2007
- Nippon Chemiphar: Uralyt, Generics Drive Business
November 26, 2007
- Toyama Chemical: License Fees Revitalize Business
November 26, 2007
- Prescription Form to Be Changed again to Promote Use of Generics
November 26, 2007
- Yakult Honsha: Pharma Sales Up 31% Driven by Elplat
November 26, 2007
- R&D NEWS IN BRIEF
November 26, 2007
- Seikagaku Corp.: Artz Drives Sales 12.9%
November 26, 2007
- REGULATORY NEWS IN BRIEF
November 26, 2007
- Nissan Chemical:Pharma Sales Down to \3,415 Mil.
November 26, 2007
- MEDICAL DEVICE NEWS IN BRIEF
November 26, 2007
- Top-4 Wholesalers Keep Operating Profit Rates Above 1%
November 26, 2007
- There Is No Legal Ground for Ban on Kongo Shinryo: Court Ruling
November 26, 2007
- Mediceo Paltac to Expand Its Share on Market for Dispensing Pharmacies
November 26, 2007
- NEW PRODUCTS／POLA Pharma Launches Estradiol Gel
November 26, 2007
- Alfresa: Good Sales to Dispensing Pharmacies Drive Business
November 26, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 26, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…